SEE NEW DATA FROM THE RESPOND REAL-WORLD EFFECTIVENESS STUDY

PURAPLY®AM SCIENTIFIC DATA

Discover the antimicrobial effectiveness of PuraPly AM in nonclinical studies.

ANTIMICROBIAL EFFECTIVENESS

In a United States Pharmacopeia Antimicrobial Effectiveness Test, PuraPly AM effectively reduced concentrations of the following microbes at days 7, 14, and 281:

PuraPly AM reduced concentrations of Aspergillus niger, MRSA, Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli in wounds

MRSA REDUCTION

Study evaluated the ability of PuraPly AM to reduce biofilm-associated bacteria (MRSA USA300, a clinically virulent strain of Staphylococcus aureus) vs 3 other treatment groups.2

  • >98% reduction of MRSA counts compared to baseline
  • >96% reduction of MRSA counts vs untreated control on all assessment days
  • Largest reduction of MRSA counts vs any of the other treatment groups
  • The only treatment to substantially reduce MRSA within 2 days

Watch principal investigator Stephen C. Davis discuss the details of the preliminary study.

SUPPORTING WOUND CLOSURE IN REAL-WORLD STUDIES

See how PuraPly AM supported healing in real-world studies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.

Contact us

Please refer to the PuraPly AM Instructions for Use for complete prescribing information.

REFERENCES:

  1. Data on file. USP Antimicrobial Effectiveness Test. Organogenesis Inc.
  2. Data on file. PDR-0001. Organogenesis Inc.